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The Angiopoietin (Angpt)-TIE signaling pathway controls vascular maturation and maintains the 2 
quiescent phenotype of resting vasculature. The contextual agonistic and antagonistic Tie2 ligand 3 
ANGPT2 is believed to be exclusively produced by endothelial cells, disrupting constitutive ANGPT1-TIE2 4 
signaling to destabilize the microvasculature during pathological disorders like inflammation and cancer. 5 
However, scattered reports have also portrayed tumor cells as a source of ANGPT2. Employing in situ 6 
hybridization-based detection of ANGPT2, we found strong tumor cell expression of ANGPT2 in a subset 7 
of melanoma patients. Comparative analysis of biopsies revealed a higher fraction of ANGPT2-8 
expressing tumor cells in metastatic versus primary sites. Tumor cell-expressed Angpt2 was dispensable 9 
for primary tumor growth, yet in-depth analysis of primary tumors revealed enhanced intratumoral 10 
necrosis upon silencing of tumor cell Angpt2 expression in the absence of significant immune and 11 
vascular alterations. Global transcriptional profiling of Angpt2-deficient tumor cells identified 12 
perturbations in redox homeostasis and an increased response to cellular oxidative stress. 13 
Ultrastructural analyses illustrated a significant increase of dysfunctional mitochondria in Angpt2-14 
silenced tumor cells, thereby resulting in enhanced ROS production and downstream MAPK stress 15 
signaling. Functionally, enhanced ROS in Angpt2-silenced tumor cells reduced colonization potential in 16 
vitro and in vivo. Taken together, these findings uncover the hitherto unappreciated role of tumor cell-17 
expressed ANGPT2 as an autocrine positive regulator of metastatic colonization and validate ANGPT2 as 18 
a therapeutic target for a well-defined subset of melanoma patients. 19 
Significance  20 
This study reveals that tumor cells can be a source of ANGPT2 in the tumor microenvironment and that 21 
tumor cell-derived ANGPT2 augments metastatic colonization by protecting tumor cells from oxidative 22 
stress. 23 
24 
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Melanoma patients with the occurrence of metastases at distant sites exhibit a modest 5-year survival 26 
rate of 23%, making metastasis the leading cause of melanoma-associated death (1). Recent advances in 27 
the development of novel targeted therapies against receptor tyrosine kinases (BRAF and MEK1/2) and 28 
immune checkpoints (PD-1, PD-L1, and CTLA-4) have significantly improved the overall survival and long-29 
term disease containment for melanoma patients.  Yet, only a fraction of patients with metastatic 30 
disease show long-term responses to these treatments while a majority will develop resistance towards 31 
these therapies (2,3). Furthermore, melanoma metastases can occur in the absence of any apparent 32 
primary tumor, indicating that tumor cell dissemination and metastatic seeding are early and parallel 33 
events to primary tumor progression (2,4). It is therefore necessary to unravel the underlying molecular 34 
mechanisms governing metastatic progression to rationally develop innovative strategies to treat 35 
metastatic melanoma.  36 
Angiopoietin-2, a contextual agonistic and antagonistic ligand of the constitutive quiescence-maintaining 37 
endothelial ANGPT1/TIE2 signaling axis has in recent years intensely been pursued as a second-38 
generation anti-angiogenic candidate molecule (5). Preclinically, genetic deletion of Angpt2 resulted in a 39 
transient delay of primary tumor growth (6). Postsurgical adjuvant administration of an ANGPT2-40 
neutralizing antibody in combination with low-dose metronomic chemotherapy restricted metastasis by 41 
quenching not only the angiogenic but also the inflammatory response of EC within the metastatic niche 42 
(7). In melanoma patients, circulating levels of ANGPT2 were associated with the progression of 43 
metastatic disease. Intriguingly, serum ANGPT2 levels were found significantly elevated in stage III/IV 44 
(metastases-bearing) but not in stage I/II (confined to the local site) melanoma patients as compared 45 
with healthy volunteers (8). These preclinical and clinical data have solidly established a crucial role of 46 
ANGPT2 during metastasis progression, particularly of melanoma metastasis, one of the earliest 47 
metastasizing tumor entities (2,4).  48 
ANGPT2 is an almost endothelial cell-specifically expressed cytokine that acts in an autocrine manner to 49 
promote vascular remodeling (9). However, few scattered publications have also reported low levels of 50 
ANGPT2 expression by tumor cells of different cancer entities (8,10-12). ANGPT2 is a secreted cytokine. 51 
Immunohistochemical analysis of tumor tissue sections therefore often results in a diffuse pattern of 52 
ANGPT2 expression, making it difficult to nearly impossible to accurately determine the cellular origin of 53 
secreted ANGPT2. Therefore, definite tracing of ANGPT2 expression within the tumor microenvironment 54 
will improve our current understanding of the relative contribution of tumor cell- versus EC-secreted 55 
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ANGPT2 and will allow to study the functional contribution of tumor cell-secreted ANGPT2 for tumor 56 
progression and metastasis.  57 
Employing in situ hybridization-based detection of ANGPT2 mRNA, we unambiguously detected ANGPT2 58 
expression in a subset of human melanoma specimens. Indeed, a higher fraction of metastatic 59 
melanoma patients expressed ANGPT2 in tumor cells when compared with the primary tumor and 60 
benign nevi patients. Based on these findings, we hypothesized that tumor cell-secreted ANGPT2 may 61 
contribute towards tumor progression and metastasis, possibly by affecting vascular functions or by 62 
acting in an autocrine manner on tumor cells. Detailed experimental analyses revealed that vascular or 63 
immune cell functions were not affected by tumor cell-secreted ANGPT2. Instead, tumor cell-derived 64 
ANGPT2 controlled metabolic functions of tumor cells and thereby promoted their metastatic 65 
colonization potential.  66 
Materials and Methods 67 
Cells 68 
Murine MT-RET (RET) melanoma cell line was established by isolating and culturing tumor cells from a 69 
spontaneously developed tumor in MT-RET transgenic mice (13). LLC were obtained from ATCC. B16F10-70 
Luc2 cells were purchased from Caliper life sciences, U.S.A. All human melanoma cells (SKMEL-173, 71 
SKMEL-28, C-32, WM266-4, A375, M37, SKMEL-147, and SKMEL-23) were kindly provided by J. Utikal. All 72 
cancer cells were cultured in DMEM high glucose (Gibco) supplemented with 10% FCS, 1% 73 
penicillin/streptomycin (Sigma) and 1x non-essential amino acid (Gibco). Human umbilical vein 74 
endothelial cells (HUVEC; Promocell) were cultured in Endopan-3 medium supplemented with growth 75 
factors (PAN Biotech GmbH). Mouse lung endothelial cells were acquired from Cell Biologics and were 76 
cultured in complete EC media (Cell Biologics). The cell lines used in this study were routinely tested for 77 
mycoplasma by PCR. RET and B16F10-Luc2 cells were transduced with lentiviral particles expressing 78 
shRNA constructs (Dharmacon): non-targeting (RHS4346), sh-1 Angpt2 (V2LMM_74366) and sh-2 79 
Angpt2 (V2LMM_68229). LLC cells were transduced with lentivirus to overexpress either Angpt2 or 80 
control Plenti vector. Control or Angpt2-silenced RET cells were transduced with lentivirus to 81 
overexpress either Angpt2 or control Plenti vector for rescuing Angpt2 downregulation.   82 
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For immunofluorescence staining, primary [rat anti-CD31 (BD Bioscience, #550300), rabbit anti-ki67 84 
(Bethyl Laboratories, #IHC-00375), rabbit anti-desmin (Abcam, #Ab15200-1)] and secondary [anti-rat 85 
Alexa488, anti-rabbit Alexa546 (Life Technologies)] were used. Nuclei were stained with Hoechst 86 
(Sigma). 87 
For Western blot analyses, primary [pERK (Cell Signaling, #4370), ERK (Santa Cruz, #sc-94), (pP38 (Cell 88 
Signaling, #9215), p38 (Cell Signaling, #9228), and β-actin (Santa Cruz, #sc-1616-R)] and secondary 89 
[horseradish peroxidase-conjugated antibodies (Dako)] were used. Proteins were detected with ECL 90 
(Pierce) and viewed using Amersham imager 600 (GE). 91 
In vivo studies 92 
Female C57BL/6N (WT) mice (8-10 weeks old) were purchased from Charles River. All mice were housed 93 
in a 12h light/dark cycle with free access to food and drinking water in specific pathogen-free animal 94 
facilities. All animal experiments were approved by the governmental (G257/18, G163/16 and G254/18 95 
from Regierungspräsidium Karlsruhe, Germany) Animal Care and Use Committees.  96 
For primary tumor experiments, mice were subcutaneously injected with 1x106 control or Angpt2-97 
silenced RET or B16F10 cells. Two weeks post tumor implantation, mice were sacrificed and tumors and 98 
blood samples were collected for further processing. For N-acetyl-L-cysteine (NAC) (Sigma, 616-91-1) 99 
experiments, treatment was initiated on the day of tumor injection. The mice received drinking water 100 
supplemented with NAC (1g/l). 101 
For LLC tumor experiments, 1x106 LLC Plenti or LLC Plenti-Angpt2 cells were inoculated subcutaneously 102 
in C57BL/6N mice. Primary tumors were surgically resected at an average size of 150 mm3. Mice were 103 
post-resection routinely checked for the experimental endpoint criteria. 104 
For experimental metastasis, 2.5x105 control or Angpt2-silenced RET or B16F10 cells were injected in the 105 
tail vein of 8-10 weeks old female WT mice. Mice were sacrificed 2 weeks after tumor cell inoculation. 106 
Lungs were harvested and the number of metastases were counted under a stereomicroscope. For NAC 107 
treatment, the treatment was initiated one day prior to tail vein injection. The mice either received 108 
regular drinking water or drinking water supplemented with NAC (1g/l). 109 
For ear tumor model, 3x105 (in 10 µl) control or Angpt2-silenced RET cells were injected in the ear 110 
dermis of 8-10 weeks old WT mice. Mice were sacrificed 2 weeks after tumor cell inoculation. Cervical 111 
LN were harvested and the incidence of melanoma metastasis was evaluated under a stereo-112 
microscope. 113 
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For in vivo lung colonization assays, 1.5x105 control (red) and Angpt2-silenced (green) cells were co-114 
injected intravenously in the tail vein of 8-10 weeks old female WT mice. After 2 weeks, mice were 115 
sacrificed and lungs were harvested. Images of the harvested lungs were taken using a 116 
stereomicroscope with fluorescence detection capabilities. Total RFP and GFP area in the lungs were 117 
calculated using Image J software.    118 
Patient samples 119 
Tissue microarrays (TMA) were kindly generated by the tissue bank of the National Center for Tumor 120 
Diseases (NCT, Heidelberg, Germany) using the paraffin-embedded human tumor specimens. 121 
Ethical approval 122 
The study was performed with archived paraffin-embedded tissue samples. The study was approved by 123 
the ethical committee of Heidelberg University (2014-835R-MA). 124 
Immunofluorescence and immunohistochemistry  125 
Fresh tissue samples were embedded in Tissue-Tek OCT and cut into 7µm thick cryosections for IF 126 
staining. Images were acquired using Zeiss Axio Scan and image analysis was performed with Fiji. 127 
For immunohistochemistry, tissue samples were fixed in Zinc-fixative and were embedded in paraffin. 128 
7µm sections were cut and stained with Hematoxylin and Eosin. For necrosis analysis, tumor sections 129 
were analyzed by a board-certified pathologist (C. Mogler).  130 
ANGPT2 staining was performed as described earlier (14). In brief, freshly-cut TMA sections were 131 
mounted on super frost glass plates and stained with anti-ANGPT2 antibody (Santa Cruz Biotechnology) 132 
using Ultraview universal HRP multimer detection kit (Ventana, USA). Tumor sections were analyzed by 133 
C. Mogler.  134 
In situ hybridization 135 
In situ hybridization was performed on TMAs using a specific probe against human ANGPT2 and 136 
RNAscope®2.5 HD-Red kit (ACD, USA), according to the manufacturer’s instructions. Afterward, the 137 
TMAs were counterstained with hematoxylin. Tumor sections were analyzed by C. Mogler. 138 
on June 24, 2020. © 2020 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 17, 2020; DOI: 10.1158/0008-5472.CAN-19-2660 
Abdul Pari, Singhal et al. 
 
 7 
Anoikis assay  139 
Tumor cells were cultured under suspension condition using ultra-low attachment plates (Costar, 140 
#CLS3471-24EA) for 48h. Thereafter, the fraction of apoptotic cells was determined by FACS-based 141 
quantitation of Annexin-V (eBioscience, #88-8007-74) and FxCycle (Invitrogen, #F10347) staining.  142 
Colony formation assay 143 
Cells were cultured under anoikis conditions for 48h. Thereafter, 600 cells were seeded in a new 6-well 144 
plate and allowed to form colonies for 1wk. Colonies were fixed and stained with crystal violet. The 145 
number of colonies was counted manually.  146 
MTT proliferation assay  147 
Cells (5,000) were seeded in a 96-well plate and allowed to adhere and grow for 48h. Cellular 148 
proliferation was analyzed using cell proliferation kit (Roche, #11465007001), according to 149 
manufacturer’s instruction. 150 
Cell adhesion assay 151 
HUVECs (2.5x105) were seeded in a 6-well plate to form a monolayer (24h). GFP-labeled tumor cells 152 
(5x105) in Opti-MEM media (Life Technologies) were seeded on the top of endothelial monolayer and 153 
allowed to adhere for 40min. Non-adherent tumor cells were washed with PBS and the count of 154 
adherent tumor cells was determined using BD CantoII. 155 
Adhesion assay 156 
96-well plates were either coated with fibronectin 10μg/ml (Sigma) or Collagen-IV 10μg/ml (Sigma) at 157 
4°C overnight or 1h at 37°C. Subsequently, 30,000 tumor cells in 100μl Opti-MEM media were seeded in 158 
octuplicates. The cells were allowed to adhere for 40min at 37°C. Non-adherent cells were removed by 159 
washing the plates with PBS. The adherent cells were stained with 0.1% crystal violet solution for 10min 160 
at RT. Next, crystal violet stain was solubilized in 100µl of methanol and measured at 550nm in a 161 
spectrophotometer. 162 
Cell migration assay 163 
A CIM plate 16 (Roche Applied Science; 8 µm pore size) was used to measure tumor cell migration on a 164 
xCELLigence system (Roche). The lower wells of the CIM plate were filled with 160 µl full media and 100 165 
µl serum free DMEM media was added on the upper wells. The plate was equilibrated for 1h at 37°C. 166 
After background measurement, 30,000 tumor cells in 30 µl serum free DMEM media were added to the 167 
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upper chamber and the CIM plate was assembled onto the xCELLigence system and placed in the 168 
incubator at 37°C. Cell migration was assessed by monitoring changes in electric impedance every 15 169 
min for 48h. The changes in cell index over time determined the slope of the real time impedance curve.  170 
Cell invasion assay 171 
Cell invasion was evaluated using BD BioCoatTMMatrigelTM invasion chamber (24 well plate, 8 mm pore 172 
size). After pre-hydration of invasion chambers for 1h, 2.5 × 105 tumor cells in 500 μL serum free DMEM 173 
were placed in the upper chamber and 750 μL of DMEM with 10% FBS was added into the lower 174 
chamber. After 24h incubation at 37 °C, chambers were washed with PBS and fixed in Roti-Histofix (4% 175 
PFA) for 10 min. Invaded cells were stained with 0.1% crystal violet solution and counted by a bright 176 
field microscope.  177 
Transmigration assay 178 
HUVEC (1×105) were plated in the top chamber of 6.5-mm/8.0-μm 0.2% gelatin-coated Transwells 179 
(Corning) overnight. Thereafter, PKH 26-labeled tumor cells (1×105) were seeded in the top chamber in 180 
serum free DMEM with DMEM containing 10% FCS also in the bottom chamber. Transwells were 181 
washed 8 h later and fixed with Roti-Histofix (4% PFA) for 10 min. Transmigrated PKH 26-labelled tumor 182 
cells were counted under a fluorescence microscope. 183 
Immune analysis  184 
Primary tumors were digested using Liberase (Roche) mix in DMEM media at 37°C for 30 min. Following 185 
ACK-lysis, single-cell suspension was equally divided, and stained for either lymphoid [CD45-PacOrange 186 
(Life Technologies, #MCD4530), CD3e-APC-e780 (eBioscience, #47-0032), CD45R(B220)-PE-Cy7 187 
(eBioscience, #25-0452), CD4-APC (BioLegend, #100412), CD8-PE (BD Pharmingen, #553033), and NK-188 
1.1-PerCP-Cy5.5 (BioLegend, #108728)] or myeloid [CD45-PacOrange (Life Technologies, #MCD4530), 189 
CD11b-PE-Cy7 (eBioscience, #25-0112), F4/80-PE (BioLegend, #123110), Ly6C-APC-e780 (BioLegend, 190 
#128025), and Ly6G-APC (BioLegend, #127613)] panel. FxCycle-violet and 20µl CountBright™ Absolute 191 
Counting Beads (Thermo Fisher Scientific, #C36950) were added to exclude dead cells and to analyze the 192 
absolute cell numbers per mg of tissue, respectively. Samples were acquired on BD Aria FusionII and 193 
were analyzed with FlowJo software. 194 
ROS analysis  195 
In vivo: Tumor tissues were processed into a single-cell suspension as described above and incubated 196 
with CellRox-Deep Red (Thermo Scientific, #C10422) for 30min at 37°C in full media (FM). Cellular ROS 197 
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was measured by quantifying the mean fluorescent intensity (MFI) of CellROX dye in FxCycle-CD45-CD31-198 
Ter119-GFP+ tumor cells using BD CantoII.  199 
In vitro: Cells were cultured in either FM or serum-starved media and kept under anoikis conditions for 200 
48h. Thereafter, cells were stained with CellRox-Deep Red as described above. Live cells were analyzed 201 
for MFI of CellRox dye.   202 
ELISA 203 
ANGPT2 protein levels in the cell culture supernatant and serum were determined using either mouse 204 
ANGPT2 (R&D, #MANG20) or human ANGPT2 (R&D, #DANG20) ELISA kits, according to the 205 
manufacturer’s protocol.  206 
 207 
Gene expression analysis 208 
Total RNA, isolated by homogenizing tumor tissue, was used for reverse transcription using QuantiTect 209 
Reverse Transcription Kit (Qiagen) according to the manufacturer’s instructions. cDNA was used for RT-210 
qPCR using TaqMan Fast Advanced Mastermix and TaqMan probes [TEK (Hs00945146_m1); ANGPT2 211 
(Hs01048042_m1); ACTB (Hs01060665_g1); Angpt2 (Mm00545822_m1); Hmox1 (Mm00516005_m1); 212 
Actb (Mm00607939-s1); MKi67 (Mm01278617_m1); Fis1 (Mm00481580_01); Dnm1l 213 
(Mm01342903_m1); Applied Biosystems] on a LightCycler-480 (Roche) system. Gene expression was 214 
calculated by ΔΔCt method.  215 
Microarray analysis 216 
Microarrays were conducted by the DKFZ Genomics and Proteomics core facility. In brief, total RNA from 217 
tumor cells was used to generate libraries which were hybridized on Affymetrix GeneChip™ Mouse Gene 218 
2.0 ST arrays (Affymetrix). Microarray data were normalized using Affymetrix Expression Console 219 
software and differential gene expression was calculated using Affymetrix Transcriptome Analysis 220 
Console. Gene Set Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) were performed to 221 
annotate the differentially regulated molecular pathways. The microarray data with the description are 222 
deposited under GEO accession no. GSE146320.  223 
Seahorse analysis  224 
Mitochondrial function of tumor cells was measured using Mito stress test in XF96 extracellular flux 225 
analyzer (Seahorse Bioscience) according to the manufacturer’s instruction. Tumor cells (10,000 per 226 
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well) were seeded in a 96-well Seahorse cell culture plate and incubated overnight. Next day, the cells 227 
were shifted to 1% O2 condition (Hypoxia) for 6h at 37°C. After hypoxia treatment, the cells were 228 
washed twice and the media was replaced with DMEM sea horse media (Seahorse Bioscience) 229 
containing 1mM pyruvate (Sigma), 2mM glutamine (Gibco), and 10mM glucose (Sigma). Next, the plate 230 
containing the cells was kept in non-humidified 37°C incubator 1h prior to start of the experiment. 231 
Oxygen consumption rate (OCR) was measured at the basal level and after addition of the following 232 
compounds: oligomycin (Sigma, 0.5 μM), FCCP, (Sigma, 0.25 μM) and rotenone (Sigma, 0.5 μM). The 233 
data were analyzed using the wave software (Seahorse Bioscience) according to the manufacturer’s 234 
instructions. Proton leak was calculated by subtracting non-mitochondrial respiration from minimum 235 
rate measurement after oligomycin injection.  236 
TCGA analysis  237 
Spearman correlation analysis of TCGA gene expression datasets from Skin Cutaneous Melanoma 238 
(SKCM) samples was performed using GEPIA web portal.  239 
Human Protein Atlas analysis  240 
Kaplan-Meier graphs were plotted from the survival information of melanoma patients extracted from 241 
Human Protein Atlas database.  242 
Transmission electron microscopy  243 
Transmission electron microscopy was performed in the DKFZ electron microscopy core facility. Tumor 244 
cells were grown on punched Aklar (EMS, Germany) under serum-starvation and hypoxic conditions for 245 
24h. Thereafter, cells were fixed in buffered aldehyde (4% formaldehyde, 2% glutaraldehyde, 1mM 246 
MgCl2, 1mM CaCl2 in 100mM Ca-cacodylate, pH 7.2), post-fixed in aqueous 1% osmium tetroxide 247 
followed by en-block staining in 1% ethanolic (75%)-uranylacetate. Following dehydration in graded 248 
steps of ethanol, the adherent cells got flat-embedded in epoxide (Glycidether, NMA, DDSA: Serva, 249 
Germany). Ultrathin 50nm sections were cut and contrast-stained with lead-citrate and uranylacetate. 250 
The sections were imaged with a Zeiss EM910 at 120kV (Carl Zeiss, Germany) and micrographs were 251 
taken with a CCD-Camera (TRS, Germany). Mitochondria with disrupted cristae structure were counted 252 
and quantification was done manually without prior-knowledge of biological groups.  253 
Statistical analysis  254 
All data are expressed as mean with error bars depicted as SD or SEM (indicated in figure legends). n 255 
represents the number of independent experiments in case of in vitro experiments and the number of 256 
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mice for in vivo experiments. Statistical analyses were performed using GraphPad Prism 6. Comparisons 257 
between two groups were made using two-tailed unpaired Student’s t-test, non-parametric Mann 258 
Whitney U-test, or paired t-test. A p-value of less than 0.05 was considered statistically significant.  259 
Results  260 
Tumor cells in melanoma patients express ANGPT2 261 
To investigate the abundance and cellular source of ANGPT2 in melanoma patients, we performed 262 
immunohistochemical staining of ANGPT2 in primary tumors and metastatic tissue biopsies. In line with 263 
previous publications, a substantial fraction (26/68) of melanoma biopsies expressed high levels of 264 
ANGPT2 (Fig. 1A, Supplementary Fig. S1A, B). A closer look at the stained tissue micro-arrays (TMA) 265 
revealed two different staining patterns – one in which ANGPT2 was confined to blood vessels (Fig. 1A, 266 
upper image) and a second with more diffuse pleiotropic presence of ANGPT2 (Fig. 1A, lower image), 267 
thereby hinting to different cellular sources of secreted ANGPT2. To conclusively determine the source 268 
of ANGPT2 in tumor tissues, we employed in situ hybridization (ISH)-based staining of ANGPT2 mRNA in 269 
an independent melanoma TMA. Indeed, ISH analysis demonstrated that tumor cells, in addition to EC, 270 
expressed ANGPT2 in a subset of melanoma biopsies (Fig. 1B). Forty-seven of 133 analyzed samples 271 
(using ISH) had detectable ANGPT2 expression (Supplementary Fig. S1A) and 23 of these showed 272 
ANGPT2 expression in tumor cells. Since serum levels of ANGPT2 had been shown to correlate with 273 
prognosis of melanoma patients, we assessed whether tumor cell-expressed ANGPT2 could serve as a 274 
predictive biomarker for melanoma progression (6). Indeed, a higher fraction (28.2%) of metastatic 275 
melanoma patient biopsies had ANGPT2 expression in tumor cells when compared with primary tumor 276 
and benign nevi samples (Fig. 1C). This implied that increased ANGPT2 expression in tumor cells was 277 
associated with metastatic progression. Moreover, analysis of Human Protein Atlas datasets revealed an 278 
inverse correlation between ANGPT2 expression levels and overall survival of melanoma patients 279 
(Supplementary Fig. S1C). Taken together, human melanoma cells express and secrete ANGPT2 and 280 
ANGPT2 expression is a prognostic marker for metastatic melanoma.  281 
Angpt2 silencing in tumor cells enhances intratumoral necrosis 282 
To examine the functional role of tumor cell-derived ANGPT2, a set of human and mouse melanoma cell 283 
lines was screened for ANGPT2 gene expression, wherein 5/8 human (Supplementary Fig. S1D) and 2/2 284 
mouse (Fig. 1D) melanoma cell lines were found positive for ANGPT2 expression. Side-by-side 285 
comparison of ANGPT2 expression levels in tumor cells with the corresponding mouse or human EC 286 
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showed that mouse tumor cells had endogenous Angpt2 levels similar to murine lung EC, whereas 287 
human melanoma cells expressed ANGPT2 to a lower extent compared with HUVEC. Despite significant 288 
Angpt2 expression, both murine melanoma cell lines lacked detectable expression of the cognate 289 
signaling receptor Tie2 (Tek; Fig. 1D). In the case of human tumor cells, 8/8 cell lines displayed low but 290 
detectable levels of TEK (Supplementary Fig. S1E). Based on endogenous ANGPT2 expression, we chose 291 
3 cell lines, including 2 murine (RET, B16F10) and 1 human (SKMEL-28), with relatively higher ANGPT2 292 
expression to determine whether these cell lines secreted ANGPT2. Indeed, all three tested cell lines 293 
secreted ANGPT2 with conditioned media concentrations ranging from 0.44 ng/ml in SKMEL-28 to 2.4 294 
ng/ml and 3.8 ng/ml in B16F10 and RET cell lines, respectively (Fig. 1E, Supplementary Fig. S1F). Tumor 295 
cell-secreted ANGPT2 may act either in a paracrine manner on stromal cells (EC, Tie2+ macrophages) or 296 
in an autocrine manner on melanoma cells. Considering that both, RET and B16F10 cells secreted much 297 
higher amounts of ANGPT2 as compared with SKMEL-28 cells, we selected these two melanoma cells for 298 
further experimentation. Additionally, the syngeneic status of RET and B16F10 cells allowed us to 299 
perform all in vivo experiments in immunocompetent mice, thereby assessing the impact of tumor cell-300 
derived ANGPT2 on all stromal components of the tumor microenvironment.  301 
To study the functional role of tumor cell-derived ANGPT2 during tumor progression, shRNA mediated 302 
knockdown of Angpt2 was performed in RET and B16F10 cells. Effective silencing of Angpt2, both at the 303 
mRNA and protein levels, was achieved in vitro using two independent shRNAs (sh-1 and sh-2; Fig. 1E, 304 
Supplementary Fig. S2A). Reduced expression of Angpt2 did not affect the proliferation of tumor cells in 305 
an in vitro MTT-based assay (Supplementary Fig. S2B). Next, to examine whether the lack of tumor cell-306 
derived ANGPT2 affected primary tumor growth, 1x106 control (non-targeting) or Angpt2-silenced 307 
tumor cells (RET and B16F10) were implanted subcutaneously in C57BL/6N mice. Mice were sacrificed 308 
14 days after tumor inoculation and primary tumor weights were measured (Fig. 2A, Supplementary Fig. 309 
S3A, B). QPCR analysis of whole tumors verified a significant downregulation of Angpt2 in both 310 
experimental models (Fig. 2B, Supplementary Fig. S3C). Further, ELISA-based quantitation confirmed a 311 
significant reduction of ANGPT2 protein in Angpt2-depleted primary tumors (Supplementary Fig. S3D). 312 
In line with our previous in vitro observations, no significant difference was observed in primary tumor 313 
growth between the non-targeting control and Angpt2-silenced tumors. In-depth histological analysis of 314 
tumor tissue sections revealed that Angpt2-silenced tumors had higher intratumoral necrosis in both 315 
tumor models as compared with control tumors (Fig. 2C, Supplementary Fig. S3E, F). Further, qPCR 316 
(Supplementary Fig. S3G, H) and immunofluorescence (IF) (Fig. 2D, Supplementary Fig. S3I, J) analyses of 317 
the proliferation maker Ki67 did not show differences between control and Angpt2-silenced primary 318 
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tumors, indicating that enhanced necrosis did not result in a reduction of tumor cell proliferation. 319 
Reintroduction of Angpt2 expression in Angpt2-depleted tumor cells abolished the intratumoral necrosis 320 
associated with the loss of Angpt2 in tumor cells (Fig. 2E, F). Thus, enhanced necrosis in Angpt2-321 
depleted tumors is resulting specifically from the ack of Angpt2 and was not due to potential shRNA off-322 
target effects. Overall, the data suggested that tumor cell-derived ANGPT2 was largely dispensable for 323 
primary tumor growth and suppressed intratumoral necrosis. 324 
Tumor cell-derived ANGPT2 does not alter tumor stroma 325 
EC-derived ANGPT2 acts autocrine on blood vessels, thereby priming otherwise, quiescent EC for 326 
sprouting angiogenesis (9). We therefore hypothesized that tumor cell-secreted ANGPT2 might act 327 
similarly to facilitate tumor neoangiogenesis and potentially defunct neoangiogenesis might have 328 
resulted in the increased intratumoral necrosis as observed in Angpt2-silenced tumors. To this end, the 329 
tumor vasculature was analyzed in control and Angpt2-silenced primary tumor samples. The IF-based 330 
vascular analysis revealed that the absence of tumor cell-secreted Angpt2 affected neither microvessel 331 
density nor pericyte coverage in both melanoma models (Supplementary Fig. S4A-D). Thus, the data 332 
excluded apparent effects of cancer cell-derived ANGPT2 on the tumor vasculature, possibly suggesting 333 
that stromal-derived ANGPT2 was sufficient to sustain tumor neoangiogenesis. 334 
Recently, ANGPT/TIE signaling has been shown to regulate tumor immune surveillance. Mechanistically, 335 
dual-inhibition of ANGPT2 and VEGFA resulted in increased tumor necrosis and enhanced antigen 336 
presentation by intratumoral phagocytes which eventually led to an increase in infiltration of CD8+ 337 
cytotoxic T-cells (15). This prompted us to test whether the increased necrosis in Angpt2-silenced 338 
tumors might be attributed to alterations in immune cell infiltration. FACS-based immune phenotyping 339 
revealed no significant differences in either lymphoid (Fig. 3A, Supplementary Fig. S4E) or myeloid (Fig. 340 
3B, Supplementary Fig. S4F) cell populations when comparing non-targeting control and Angpt2-silenced 341 
tumors. Therefore, the data ruled out a possible contribution of immune cells in enhancing tumor 342 
necrosis in Angpt2-silenced tumors. 343 
ANGPT2 affects intracellular oxidative stress signaling  344 
With no detectable alterations in the vascular architecture and immune cell infiltration, we next 345 
investigated possible autocrine effects of Angpt2 silencing on tumor cells. To this end, global 346 
transcriptomic profiling of in vitro-cultured non-targeting control and Angpt2-silenced tumor cells was 347 
performed to trace changes of transcriptional gene signatures. Gene set enrichment analysis (GSEA) 348 
revealed that Angpt2 knockdown in tumor cells perturbed cellular redox homeostasis as indicated by 349 
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the enrichment of gene sets involved in the biosynthesis of reactive oxygen species (ROS) and 350 
subsequent cell death in response to oxidative stress (Fig. 4A). Additionally, pathways regulating 351 
metastasis, the antioxidant stress response and mitochondrial function were found regulated in Angpt2-352 
silenced tumor cells (Fig. 4A, Supplementary Fig. S5A, B). Indeed, the NFE2L2 (NRF2) signaling pathway, 353 
which underlines one of the major cellular defense mechanisms to resolve cellular oxidative stress, was 354 
found downregulated in Angpt2-silenced tumor cells (Fig. 4A) (16). Therefore, enhanced production of 355 
ROS together with crumbling cellular antioxidative defense mechanisms may have led to elevated levels 356 
of intracellular oxidative stress in the absence of Angpt2 expression. Indeed, in silico analysis of TCGA 357 
human skin cutaneous melanoma (SKCM) dataset revealed a positive correlation between ANGPT2 and 358 
NFE2L2 expression (Fig. 4B), substantiating our findings from Angpt2-deficient murine melanoma cells. 359 
Furthermore, the expression of HMOX1, a key downstream enzyme in the NRF2 signaling cascade and 360 
scavenger for cellular ROS (16), also positively correlated with ANGPT2 in the TCGA-SKCM dataset (Fig. 361 
4B).  362 
To confirm these in vitro findings in vivo, we assessed the expression of Hmox1 in control and Angpt2-363 
silenced tumors. Corroborating our earlier findings, Angpt2-silenced tumors manifested lower 364 
expression of Hmox1 as compared with control tumors (Fig 4C, Supplementary Fig. S6A). To examine 365 
whether the reduced expression of Hmox1 resulted in perturbed redox homeostasis, intracellular ROS 366 
levels were measured in tumor cells isolated from primary tumors. Increased ROS levels were detected 367 
in Angpt2-silenced as compared with control tumor cells, thereby implying a malfunctioning redox 368 
homeostasis (Fig. 4D, Supplementary Fig. S6B). Interestingly, in vitro-cultured Angpt2-deficient tumor 369 
cells did not show any change in ROS production under normal culture conditions as compared with 370 
control cells (Supplementary Fig. S6C). Yet, under serum starvation, Angpt2 silencing led to a significant 371 
increase in intracellular biosynthesis of ROS (Supplementary Fig. S6C), possibly capturing the nutrition-372 
deprived in vivo conditions. Further, restoring Angpt2 expression in Angpt2-silenced tumor cells rescued 373 
the ROS levels to homeostatic conditions (Supplementary Fig. S6D).  374 
Enhanced ROS production has previously been reported to induce necrosis (5). This led us to 375 
hypothesize that increased ROS levels in Angpt2-depleted tumors could have resulted in the observed 376 
necrosis phenotype. To further experimentally validate this hypothesis in vivo, mice implanted with 377 
either control or Angpt2-silenced tumor cells were administered ROS inhibitor N-acetyl-L-cysteine (NAC) 378 
in drinking water (Supplementary Fig. S6E). NAC treatment abrogated the previously-observed increase 379 
in intratumoral necrosis in Angpt2-depleted as compared with non-targeting control tumors (Fig. 2C, 380 
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Supplementary Fig. S6F, G). These data indicated that enhanced intracellular ROS in Angpt2-depleted 381 
tumors may have resulted in increased intratumoral necrosis.  382 
The rapid growth of a primary tumor is often accompanied by nutrient deprivation and induction of 383 
hypoxia in the center of tumor tissue (17). Such a hostile environment can have detrimental effects on 384 
mitochondrial function in tumor cells. Subsequently, mitochondria lose their morphology and cristae 385 
structure, essential determinants of their physiological function, and begin to produce high levels of ROS 386 
(18,19).  To investigate whether mitochondrial morphology was altered in Angpt2-silenced tumor cells, 387 
we performed ultrastructural analyses of tumor cells cultured under different conditions (hypoxia and 388 
serum starvation) by transmission electron microscopy. Under normoxic conditions, no significant 389 
differences in the mitochondrial structure was observed upon Angpt2 knockdown (Supplementary Fig. 390 
S7A, B). Yet, under hypoxic conditions, mitochondrial morphology was highly irregular with near-391 
complete loss of cristae structure in Angpt2-silenced as compared with control tumor cells (Fig. 4E). 392 
Concurrently, the number of fragmented mitochondria per cell was significantly increased (Fig. 4F).  393 
Expression analysis of genes involved in mitochondrial dynamics showed a reduced expression of Drp1 394 
(Dnm1l) and Fis1 in Angpt2-depleted primary tumors (Supplementary Fig. S7C, D). DRP1 and FIS1 are 395 
required for maintaining mitochondrial integrity, therefore their downregulation highlights perturbation 396 
in mitochondrial function in the absence of Angpt2 expression (20,21).   397 
To determine an unambiguous readout of mitochondrial function, a Seahorse Mito Stress experiment 398 
was conducted to determine the mitochondrial bioenergetic profile of tumor cells. Proton leak, a key 399 
parameter in a Seahorse experiment, represents the oxygen consumption rate (OCR) associated with all 400 
ion movement across the inner mitochondrial membrane during ATP synthesis (22). Indeed, the loss of 401 
ANGPT2 resulted in a significant reduction of proton leak in tumor cells, thereby confirming diminished 402 
mitochondrial function (Fig. 4G). Furthermore, elevated ROS levels, due to curtailed mitochondrial 403 
function, have been shown to activate MAPK stress signaling (23). Concomitantly, increased 404 
phosphorylation levels of ERK and P38, key components of the MAPK pathway, were observed in 405 
Angpt2-silenced primary tumors when compared with control tumors (Fig. 4H, Supplementary Fig. S7E). 406 
Overall, the data established an important role of tumor cell-expressed Angpt2 in maintaining 407 
mitochondrial function and redox homeostasis.  408 
Tumor cell-expressed Angpt2 facilitates metastasis 409 
To investigate if Angpt2 deficiency affected the metastatic potential of melanoma cells, tumor cells were 410 
intravenously injected to initiate an experimental metastasis assay. Loss of tumor cell-expressed Angpt2 411 
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resulted in a significant reduction in lung metastases in both melanoma models (Fig. 5A, B, 412 
Supplementary Fig. S8A, B). To circumvent the substantial heterogeneity of the experimental metastasis 413 
assay, we performed an indexed analysis by co-injecting RFP-labeled control and GFP-labeled Angpt2-414 
silenced cells in mice and measured the composition of lung metastases ex vivo 14 days after 415 
intravenous injection. Unambiguously, Angpt2-silenced tumor cells exhibited reduced metastatic 416 
potential as compared with control cells (Fig. 5C, D, Supplementary Fig. S8C, D). Moreover, rescuing 417 
Angpt2 expression in Angpt2-depleted cells reversed the observed decline in metastasis (Fig. 5E, F), 418 
thereby indicating that reduction of metastasis was due to the loss of Angpt2. Next, we employed a 419 
cervical LN metastasis model in which intradermally-inject tumor cells in the ear colonize the draining 420 
LN. Similar to the lung experimental metastasis assay, depletion of tumor cell-Angpt2 reduced the 421 
incidence of cervical LN metastasis (Fig. 5G, H). To substantiate the findings in a spontaneous metastasis 422 
model, we utilized the LLC post-surgical model in which lung metastases develop after surgical removal 423 
of the primary tumor (Supplementary Fig. S8E). Indeed, there was a significant decrease in post-surgical 424 
survival of mice implanted with Angpt2-overexpressing as compared with control LLC cells 425 
(Supplementary Fig. S8F, G). 426 
Based on the above findings, we hypothesized that the observed decrease in metastatic capability of 427 
Angpt2-depleted cells could be due to enhanced oxidative stress. To experimentally investigate this 428 
hypothesis, mice injected intravenously with either control or Angpt2-silenced RET cells were treated 429 
with ROS scavenger NAC. In line with the primary tumor data, administration of NAC in mice injected 430 
with Angpt2-deleted tumor cells rescued the observed reduction of metastasis upon loss of Angpt2 in 431 
tumor cells (Fig. 6A-C). Collectively, these experiments underline tumor cell-expressed Angpt2 as a 432 
crucial regulator of their metastatic capability, primarily by altering intracellular ROS and subsequent 433 
cellular oxidative stress.  434 
Next, we performed a set of experiments to mechanistically decipher the role of tumor cell-expressed 435 
Angpt2 on different steps of the metastatic cascade experienced by the tumor cells in an experimental 436 
metastasis model. Examining the role of migration, anoikis-induced tumor cell death, tumor cell 437 
adhesion to EC and to ECM depicted no significant differences between control and Angpt2-silenced 438 
tumor cells, suggesting that tumor cell-expressed Angpt2 did not impact early steps of the metastatic 439 
cascade (Supplementary Fig. S9A-H). Subsequently, we assessed whether tumor cell-derived ANGPT2 440 
was required for tumor cell invasion and transmigration. Downregulation of Angpt2 hindered the 441 
capability of tumor cells to invade through the basement membrane and transmigrate across the 442 
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endothelial barrier (Supplementary Fig. S10A-H). Further, we evaluated whether tumor cell-expressed 443 
Angpt2 affected the ability of tumor cells to colonize the metastatic site. To simulate in vivo conditions 444 
for colonization, tumor cells were treated under anoikis conditions for 48h and a colony formation assay 445 
was initiated thereafter. Lack of Angpt2 decreased the colonization potential of tumor cells as indicated 446 
by sharp reduction in the number of colonies (Supplementary Fig. S11A-D). Concordantly, 447 
overexpressing Angpt2 in Angpt2-depleted tumor cells recovered the colonizing capability of the tumor 448 
cells (Supplementary Fig. S11E,F). These findings demonstrate that tumor cell-expressed Angpt2 449 
promoted metastasis by facilitating the colonization process. 450 
Discussion  451 
The incidence of melanoma has been steadily rising during the last 50 years. While the 5-year survival 452 
rate for patients with locally-contained (stage I) melanoma is 98%, distant metastasis is often life-453 
threatening with a modest survival rate of 23% (1). This can largely be attributed to early metastatic 454 
spread and non-reliable detection of primary lesions. It is estimated that approximately 10% of 455 
melanomas go undetected with the current diagnostic methods (4). Previously, we have established 456 
serum ANGPT2 as a reliable biomarker for melanoma progression, especially to distinguish stage III/IV 457 
from primary melanomas (8). Indeed, patients with distant organ metastasis (stage IV) had on average 458 
4-fold higher levels of serum ANGPT2 when compared with patients with lymph-node (LN)-restricted 459 
tumors (stage III). Intriguingly, immunoperoxidase-based analysis of advanced-stage tumors revealed a 460 
weak but consistent expression of ANGPT2 in tumor cells. These data raised the question of relative 461 
abundance and functional role of tumor cell-expressed ANGPT2 during melanoma metastasis.  462 
Employing a wide array of clinical and preclinical analysis, the present study demonstrates that (1) 463 
tumor cells serve as a source of ANGPT2 in a fraction of melanoma patients; (2) loss of endogenous 464 
Angpt2 expression in tumor cells neither affects primary tumor growth, nor does it influence tumor 465 
angiogenesis and the immune landscape, but rather results in enhanced intratumoral necrosis; (3) 466 
Angpt2 silencing in tumor cells perturbed cellular redox homeostasis by augmenting mitochondrial 467 
dysfunction; and (4) Angpt2 silencing in melanoma cells profoundly suppressed lung metastases due to 468 
enhanced ROS production, which led to reduction in colonization potential of Angpt2-silenced tumor 469 
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cells. Together, these data reveal novel functions of cancer cell-derived ANGPT2 during melanoma 470 
progression. 471 
Following the clinical approval of VEGF/VEGFR-targeting drugs, ANGPT/TIE signaling was pursued as 472 
second generation angiogenesis-regulating vascular tyrosine kinase system for its ability to 473 
synergistically enhance the efficacy of approved anti-angiogenic therapies (5). Similar to VEGF, ANGPT2 474 
was found upregulated in both primary tumor tissues and the circulation of multiple cancer entities. Yet, 475 
whereas VEGF is primarily secreted by the tumor cells, ANGPT2 is almost exclusively produced by tumor-476 
associated EC (24). Yet, some melanoma biopsies from patients with advanced disease manifested a 477 
rather diffuse staining of ANGPT2 compared with the confined blood vessel-restricted staining in other 478 
tumors.  Likewise, several cultured human melanoma cell lines have been reported to express ANGPT2 479 
(8). Here, employing in situ hybridization, we unambiguously traced the cellular source of ANGPT2 in 480 
human tissue microarrays. Clearly, tumor cells in a subset of human melanomas expressed and secreted 481 
ANGPT2. However, unlike the granular pattern of ANGPT2 staining observed in EC due to its localization 482 
in Weibel-Palade bodies, ANGPT2 staining in TMA sections had a uniform cytoplasmic localization 483 
pattern in tumor cells (25). This suggests that ANGPT2 in tumor cells may not be stored and rapidly 484 
released upon stimulation.   485 
Evaluation of ANGPT2 expression in melanoma patient samples demonstrated that the fraction of 486 
patients with tumor cell-expressed ANGPT2 was much higher in the metastatic specimens as compared 487 
with either nevus or primary melanomas, thereby suggesting a crucial role of tumor cell-expressed 488 
ANGPT2 for melanoma metastasis.  489 
Host-derived ANGPT2 has been shown to affect early stages of primary tumor growth but is largely 490 
dispensable for the growth of established tumors (6). Concurrently, administration of ANGPT2-491 
neutralizing antibody delayed primary tumor growth of xenografted human cells (26). Mechanistically, 492 
ANGPT2-blockade restricted EC proliferation and enhanced pericyte coverage for improved perfusion 493 
properties. Apart from the proangiogenic function of ANGPT2, ectopic overexpression of ANGPT2 in 494 
human breast cancer cells has been described to act autocrine, thereby promoting cellular invasiveness 495 
to facilitate distant metastasis (27). Likewise, ANGPT2 overexpression in glioma cells induced tumor cell 496 
invasion in an MMP2-dependent manner (28). Thus, previous publications have hinted towards an 497 
autocrine, angiogenesis-independent role of cancer cell-expressed ANGPT2 during tumor progression. 498 
However, the previous studies have relied on exogenous overexpression of ANGPT2, which often tends 499 
to flood the cellular environment with non-physiological amounts of protein, thereby interfering with 500 
on June 24, 2020. © 2020 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 17, 2020; DOI: 10.1158/0008-5472.CAN-19-2660 
Abdul Pari, Singhal et al. 
 
 19 
their normal cellular function (29). To circumvent this artificial gain-of-function approach, we utilized 501 
two mouse melanoma cell lines, RET and B16F10, with high endogenous expression of Angpt2, similar to 502 
mouse lung EC. ShRNA-mediated knockdown of Angpt2 in tumor cells did not alter primary tumor 503 
growth. Further, tumor cell-specific silencing of Angpt2 neither affected tumor vasculature nor the 504 
immune milieu. The loss of tumor cell-secreted ANGPT2 was possibly compensated by the host 505 
endothelium. Surprisingly though, primary tumors arising from Angpt2-silenced melanoma cells 506 
displayed increased intratumoral necrosis when compared with non-targeting control tumors, thereby 507 
emphasizing a protective role of tumor cell-expressed Angpt2 during primary tumor growth.  508 
Comparative transcriptomic analysis of control and Angpt2-silenced tumor cells identified perturbations 509 
in intracellular redox homeostasis. Angpt2 deficiency in tumor cells positively correlated with gene sets 510 
involved in ROS biosynthesis and subsequent cell death due to oxidative stress. In turn, lack of ANGPT2 511 
led to downregulation of NFE2L2 targets. NFE2L2 (Nrf2), an upstream transcriptional regulator for 512 
multiple ROS-scavenging enzymes, protects a cell from oxidative damage (16). Indeed, tumors arising 513 
from Angpt2-silenced melanoma cells showed reduced expression of Hmox1 (a downstream effector of 514 
NFE2L2), and recorded higher levels of intracellular ROS as compared with control tumors. Moreover, 515 
antioxidant treatment of mice bearing Angpt2-depleted primary tumors resulted in reduction of overall 516 
intratumoral necrosis. This implied that intracellular ROS generated after Angpt2-silencing in tumor cells 517 
drives necrosis in primary tumors. Correspondingly, analysis of TCGA-SKCM data set revealed a positive 518 
correlation between ANGPT2 and NFE2L2/HMOX1 expression, further bolstering a crucial role of tumor 519 
cell-expressed ANGPT2 in minimizing stress-induced oxidative damage.   520 
Unrestricted growth of primary tumors results in a hypoxic and nutrient-deprived core (30). In a hypoxic 521 
microenvironment, tumor cells adapt their mitochondrial function to slow down oxidative 522 
phosphorylation and hyperactivate NRF2 pathway to lower intracellular levels of ROS (19). Any 523 
imbalance in these protective mechanisms may result in the accumulation of ROS and sustained 524 
oxidative damage. Melanoma cells quickly adapt to the hypoxic conditions as they did not display major 525 
alterations in the mitochondrial ultrastructure. Nevertheless, in the absence of Angpt2 expression, 526 
melanoma cells witnessed a higher fraction of dysfunctional mitochondria and subsequent reduction in 527 
energy production. Hence, enhanced expression of Angpt2 in melanoma tumor cells acts as a defense 528 
mechanism against cellular stress. These findings are in line with a recent publication highlighting the 529 
protective role of ANGPT2 on hepatocellular cancer cell line HepG2 under Doxorubin-induced cytotoxic 530 
stress by reducing ROS production and preserving mitochondrial function (31). 531 
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Despite no apparent effects on primary tumor growth, Angpt2-silenced melanoma cells led to reduced 532 
lung metastasis in experimental metastasis assays. Mechanistically, Angpt2 silencing restricted the 533 
efficacy of metastatic colony formation of melanoma cells. Likewise, ectopic expression of ANGPT2 in 534 
PDAC xenografts was reported to display an enhanced rate of lymphatic metastasis (32). Successful 535 
colonization at a distant organ site requires a single-seeded tumor cell to survive in a hostile 536 
microenvironment and to overcome a variety of extracellular and intracellular stresses. Our molecular 537 
data underline an important role of tumor cell-expressed Angpt2 in maintaining intracellular oxidative 538 
balance and preserving mitochondrial function. Notably, ROS scavenger NAC effectively reinstated the 539 
metastatic capacity of Angpt2-depleted tumor cells. Thus, tumor cell-Angpt2 protects melanoma cells 540 
from oxidative stress and ensures their survival during the metastasis process.  These mechanistic 541 
findings explain why a higher fraction of metastatic melanoma biopsies displayed tumor cell-expressed 542 
ANGPT2.  543 
In summary, the present study, by establishing spatial distribution of ANGPT2 expression in metastatic 544 
melanoma, has revealed the cellular source of ANGPT2 in melanoma and shed light on the molecular 545 
and functional contribution of tumor cell-expressed Angpt2 during metastasis. The findings expand the 546 
hitherto endotheliocentric view of angiopoietin functions and validate ANGPT2 as a therapeutic target 547 
for a well-defined subset of melanoma patients.  548 
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Figure 1. Melanoma cells express ANGPT2. (A) Immunohistochemical analysis of ANGPT2 expression in 
tissue biopsies of human melanomas. Scale bar: 100µM. (B) Tissue sections from melanoma patients 
were stained with ANGPT2 RNASCOPE probe. Square boxes depict regions of interest (ROIs) at a higher 
magnification. Scale bar: 50µM. (C) Quantitation of the number of patients with detectable expression 
of ANGPT2 in tumor cells of benign melanocytic nevi (n=8), primary (n=33), and metastatic melanomas 
(n=92). *, p<0.05, Chi-square test. (D) Angpt2 and Tek expression were quantified using qRT-PCR in 
mouse melanoma cell lines and mouse lung EC (ND= non-detected). (E) ANGPT2 ELISA was performed to 
quantify ANGPT2 protein in supernatants of control and Angpt2 knockdown cells (sh-1 and sh-2) in RET 
and B16F10n=3; mean ± SD). *, p<0.05, **, p<0.01, two-tailed unpaired Student’s t-test.  
Figure 2. Angpt2 knockdown in tumor cells does not alter primary tumor growth. (A) Tumor weight at 
day 14 after primary tumor inoculation of control RET and knockdown cell lines (n=12; mean ± SD). (B) 
Angpt2 expression in control and Angpt2 knockdown RET primary tumors quantified by qRT-PCR (n=8-9; 
mean ± SD). *, p<0.05, ****, p<0.0001, Mann Whitney U test. (C) On the left, representative H&E 
images of control and Angpt2 knockdown RET primary tumors are shown. Arrowheads indicate necrotic 
area. Scale bar: 1mm. On the right, quantitation of necrotic area is shown (n=9-11 mean ± SD). *, 
p<0.05, Mann Whitney U test. (D) On the left, representative images of tumor sections stained with KI67 
(in red). Scale bar: 200µm. On the right, quantitation of KI67-positive area normalized to DAPI area in 
control and Angpt2 knockdown RET primary tumors (n=5-6; mean ± SD). (E) ANGPT2 ELISA was 
performed to quantify ANGPT2 protein levels in supernatants of control+Plenti, sh-2+Plenti and sh-
2+Plenti Angpt2 cells in RET (n=3; mean ± SD). *, p<0.05, **, p<0.01, two-tailed unpaired Student’s t-
test. (F) On the left, representative H&E images of control+Plenti, sh-2+Plenti and sh-2+Plenti Angpt2 
RET primary tumors are shown. Arrowheads indicate necrotic area. Scale bar: 1mm. On the right, 
quantitation of necrotic area is shown (n=6 mean ± SD). *, p<0.05, Mann Whitney U test. 
Figure 3. Angpt2 knockdown in tumor cells does not impact immune cell infiltration. (A-B) FACS-based 
immune analysis was performed control and Angpt2 knockdown RET primary tumors on day 14 after 
tumor implantation. Shown are the quantitation of tumor infiltrating lymphoid (A) and myeloid cells (B) 
(n=9-11; mean ± SD). All comparisons were rendered non-significant by Mann Whitney U test. 
Figure 4. Tumor cell-expressed Angpt2 modulates ROS and mitochondrial homeostasis. (A) On the left, 
heatmap depicting differentially regulated genes between control- and Angpt2-silenced tumor cells. On 
the right, gene set enrichment analysis identifying alterations in pathways involved in maintaining 
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oxidative homeostasis (NES=normalized enrichment score). (B) Spearman correlation analysis of 
ANGPT2, NFE2L2, and HMOX1 in cutaneous melanoma (SKCM) dataset from TCGA database. (C) Hmox1 
expression in control and Angpt2 knockdown RET primary tumors was quantified using qRT-PCR (n=8-9; 
mean ± SD). *, p<0.05, Mann Whitney U test. (D) FACS analysis of ROS levels in control and Angpt2 
knockdown RET primary tumors (n=4-5; mean ± SD). *, p<0.05, Mann Whitney U test. (E) Representative 
electron microscopic images depicting morphological changes in mitochondria of wild type and Angpt2-
silenced RET tumor cells. Cells were kept under 1% O2 and serum starvation condition for 24h before 
processing for electron microscopy. Square boxes depict ROIs at higher magnification. Scale bar: 2µm. 
(F) Quantitation of fragmented mitochondria per cell (n=16-19 cells/condition; mean ± SD). *, p<0.05, 
Mann Whitney U test. (G) Proton leak in control and Angpt2 knockdown RET tumor cells was measured 
in a Seahorse Mito Stress experiment. Prior to Seahorse analysis, cells were kept under 1% O2 for 6h 
(n=5; mean ± SD). *p<0.05, **p<0.01, two-tailed paired Student’s t-test. (H) Western blot analysis was 
performed for phospho-ERK, phospho-P38, total-P38, and total-ERK in control and Angpt2 knockdown 
RET primary tumors. Actin was used as a loading control (n=6).  
Figure 5. Tumor cell-expressed Angpt2 promotes metastasis. (A) Control or Angpt2-deficient RET cells 
were injected into the tail vein of C57BL/6N mice. Mice were sacrificed after 14 days. Shown are the 
representative images of lung metastatic foci imaged under a stereomicroscope. Scale bar: 5mm. (B) 
The graph represents the quantitation of lung metastatic foci (n=9; mean ± SD). *, p<0.05, **, p<0.01, 
Mann Whitney U test. (C) Control (in red) and Angpt2-silenced (in green) RET tumor cells were co-
injected intravenously in mice. Lungs were harvested 14 days after tumor cell inoculation and visualized 
under a fluorescent dissection microscope. Representative images of lung metastatic foci are shown. 
Scale bar: 2mm. (D) Quantitation of lung colonization by control (in red) or Angpt2-silenced (in green) 
RET tumor cells. The area of each metastatic colony (RFP/GFP) was normalized to the combined 
fluorescent area (n=5-6; mean ± SD). (E) Control+Plenti, sh-2+Plenti and sh-2+Plenti Angpt2 cells were 
injected into the tail vein of C57BL/6N mice. Mice were sacrificed after 14 days. Shown are 
representative images of lung metastatic foci imaged under a stereomicroscope. Scale bar: 5mm. (F) The 
graph represents the quantitation of lung metastatic foci (n=6; mean ± SD). **, p<0.01, Mann Whitney U 
test.  (G)  WT C57BL/6N mice were intradermally injected with either 300,000 control or Angpt2 
knockdown RET tumor cells in the ear and regional LN were collected 2 weeks later. Representative H&E 
images of LN. Arrowheads indicate detectable metastases. (H) The incidence of LN metastasis is 
depicted (n=6). 
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Figure 6. Administration of NAC rescues metastasis. (A) Schematic illustration of the rescue experiment 
to investigate the influence of ROS on regulating tumor cell-Angpt2 mediated metastasis. (B) Control or 
Angpt2-deficient RET cells were injected into the tail vein of C57BL/6N mice. Mice were administered 
either regular water or water containing 1g/l NAC.  Mice were sacrificed after 14 days. Shown are the 
representative images of lung metastatic foci imaged under a stereomicroscope. Scale bar: 5mm. (C) 
The graph represents the quantitation of lung metastatic foci (n=12; mean ± SD). *, p<0.05, **, p<0.01, 
Mann Whitney U test.  
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